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true incongruity between drug intake, nurse
documentation and physicians’ orders
Inbal Cohen-Glickman1, Yosef S Haviv2* and Matan J Cohen3Abstract
Background: Hemodialysis patients (HD) need to adhere to a complex medication regimen. Because their daily pill
burden is one of the highest reported, poor compliance is a major cause of therapeutic failure. The primary aim of
this study was to define patterns of medication prescription, intake and documentation among HD patients.
Methods: HD patients treated between 2007 and 2009 and assigned to the largest health service provider in Israel
were randomly selected. Drug practices were abstracted from their records and compared to electronic pharmacy
data. The discrepancy between drug intake reports and the actual purchase was measured to estimate adherence.
Drug purchase, intake report and physician order were plotted in complementing diagrams to appreciate
consistency and discrepancy patterns.
Results: The study included full analysis of 75 patients. The mean overall drug adherence was 56.7% (95% CI 53.6-59.9%),
varying among drug families and over time. Often, there was a systematic disengagement between the nurses’
documentation and the actual patient purchase. Specifically, we observed either different quantities of medication use,
improper documentation of a non-purchased drug, drug purchase without nurse documentation and futile
physician attempts to modify prescriptions of unpurchased medication. We found a high rate of physician order
turbulence for active vitamin D and calcium.
Conclusions: Drug prescription, documentation and adherence are incongruent and their mismatches are
diverse. Summary estimates do not divulge the extent of these disparities. These system-wide communication
failures compromise patient care. Strategies to promote system reconciliation and reasonable medication
prescription are in need.
Keywords: Hemodialysis, Adherence, Medications, Pharmacy, Physician ordersBackground
Hemodialysis (HD) patients are prescribed numerous
oral medications [1], averaging 17 to 25 doses per day
[2,3]. This high medication burden results from the
complexity of end stage renal disease and its comorbidi-
ties [4]. Previously, patterns of medication use in USRDS
HD patients were reported using descriptive analyses
where the rate of non-adherence to medications in HD
patients ranged from 15.4% to 50.2% [4-7], culminating
to 74% when phosphate binders were considered [8].* Correspondence: yhaviv@hadassah.org.il
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article, unless otherwise stated.Because non-compliance with prescribed treatment in
the general population, especially medications, increases
both the cost of health-care and the likelihood of hos-
pital admissions [8], the World Health Organization has
set action-plans to improve general patient adherence to
long-term therapies [1,9].
Integrated care for HD patients is a complex treatment
mandating four different types of adherence: medication
adherence, dietary restrictions, regular attendance of dia-
lysis sessions and keeping up with scheduled appoint-
ments. While non-adherence to HD sessions, in the
form of missing or shortening sessions, is associated
with higher mortality [6,9], it is assumed, but not
proven, that non-adherence to medications in general,d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this

















ACE inhibitors and ARB’s* 27 6.0
Captopril, ramipril, enalapril, losartan, cilazapril,
valsartan
Furosemide 32 7.1
Calcium Chanel Blockers 33 7.3
Felodipine,amlodipine,nifedipine,
verapamil,lercandipine
Beta Blockers 46 10.2




Calcium Carbonate 67 14.9
Alfacalcidol 68 15.1
Total 449 100.0
*Includes 4 cases of combined ARB’s and Hydrochlorothiazide in one pill.
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sociated with unfavorable outcomes in HD patients.
The terminology, definitions, and methods used to
determine medication adherence vary and include
medication possession ratio, discontinuation and con-
tinuation rates, switching rates, treatment gaps and
turbulence [10,11]. While current methods to assess
adherence often rely on patient self-report [2,12,13],
thereby limiting cross-study comparisons, only a few
studies have systematically compared the properties of
different adherence measures [14,15]. In this study, we
sought to critically measure medication adherence in
HD patients over a long period and to evaluate drug-
related practices by nurses and nephrologists. We
compiled all documented medication prescription,
drug purchase and reported intake into a single re-
pository using pharmacy electronic medical records
and review of HD units’ medical files.
Methods
Patients
This study was exempted from the requirement to obtained
patient consent for inclusion in the study. A General IRB
approval from the Hadassah Medical Organization Helsinki
committee was obtained for comprehensive retrospective,
non-interventional, epidemiology research in dialysis pa-
tients. This approval was given as these studies do not
compromise patient autonomy, do not influence the care
patients receive. In many cases, due to the historical-
retrospective nature, the study includes patients who are
already deceased. Access to patient database and use of
patient data are allowed, so long as research records and
report are anonymous.
The study participants were treated in seven outpatient
HD units directed by nephrologists affiliated with the
Hadassah-Hebrew University Medical Center, Jerusalem,
Israel. The majority (~65%) of our patients are insured by
Clalit Health Services (CHS), the largest health mainten-
ance organization in Israel, which provided electronic
pharmacy drug dispensing data for its HD patients. There
were no minors in the study.
Of all chronic prevalent HD patients insured by CHS and
treated between July 1st, 2007 and July 1st, 2009, half of pa-
tients were randomly selected using an arbitrary digit of
their ID number. Exclusion criteria included acute kidney
injury, dialysis start date before January 1st, 2006 and
age <18 years. Censorship criteria were: kidney transplant-
ation, death, loss to follow-up and end of follow-up period.
Medications
The study included 13 different groups of oral drugs
commonly prescribed to HD patients (Table 1). In the
current study we documented oral drug intake that
could be further grouped into three major drug groups:drugs for atherosclerosis (aspirin, nitrates, statins), drugs
for heart failure/arrhythmia/fluid overload/blood pres-
sure (ACE inhibitors/ARB, beta blockers, calcium chan-
nel blockers, doxazosin, furosemide, anti-arrhythmics),
and mineral bone disease agents (calcium carbonate,
alfacalcidol). In addition, data were collected for oral hy-
poglycemics and anti-depressants. At the time of the
study only a minority of patients were prescribed non
calcium-based phosphate binders, thereby resulting in
exclusion of this class. Oral anticoagulants were ex-
cluded due to overlap of prescription with general prac-
titioners and weekly dose changes.
Medication practice in HD units
Patient drug intake is commonly recorded in HD units
on a monthly basis by the nursing staff via direct patient
questioning. Next, during the physician’s visit, the medi-
cation list serves as the basis for new orders or dose ad-
justments after obtaining new clinical and laboratory
data. We used the nurses’ manual drug form presented
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take. We next obtained information about drugs actually
purchased each month from the CHS electronic data-
base. Because HD patients are exempt from payment
when purchasing most disease-related drugs through
CHS pharmacies, drug purchase elsewhere is unlikely.
We recorded for each drug: a) the amount of pills actu-
ally purchased every month, as recorded in the elec-
tronic pharmacy database; b) the amount of medication
supposedly consumed, recorded in the nurse reports;
c) physicians’ recorded medication decisions, i.e. change
of regimen/dosage (stop, increase or decrease dose, or
start a new medication).
Electronic pharmacy database
In CHS pharmacies medications can be purchased in three-
month intervals. To correct for potential adherence under-
estimation, we standardized episodes of excess medication
purchase intake into one month purchase. For example,
when a patient purchased pills sufficient for more than one
month with no purchase on the following two months, we
allowed the excess amount of pills to be normalized per
month. We did not perform correction for excess medica-
tion purchase of calcium carbonate and activated vitamin D
analogs (alfacalcidol) since there were frequent changes in
doctors’ orders for these drugs, often on a monthly basis.
Drugs from the same class were considered interchangeable
for the purpose of adherence estimation. We documented
switches between drugs of the same family in the doctor’s
orders column.
Nurse reports
The nurses’ reports served as the basis to calculate the
expected number of medications consumed monthly.
Textual comments could not be quantified and were not
included in our estimation of adherence. This potential
bias might skew our analyses towards overestimation of
adherence and under-estimation of non-adherence. How-
ever, nurses rarely used text to document the amount of
pills taken (“as needed”, “sometimes forgets” etc.). We also
corrected for any discrepancy which could arise from pur-
chasing packages of 28 pills when nurse documented 30
pills purchases. When a nurse documented a range of
doses instead of a fixed quantity, we used the average
amount for calculations. For example, if a patient was
documented to use 60–90 pills monthly, we considered it
as 75 pills.
Calculation of adherence
To measure adherence we assumed that all nurse-
documented drug information was available to the neph-
rologist from the medical file. In cases where there were
no new orders, the medication lists were regarded as ap-
proved by the nephrologists. In the following month wechecked whether the patient purchased the drugs again
using methodology as described above. We defined ad-
herence or non-adherence as a dichotomous variable.
For each drug we compared the number of months the
drug was actually purchased to the number of months of
declared drug intake as reported by the patients to the
nurses. This ratio was defined as patient adherence (%).
To avoid non-adherence designation due to ignorance of
doctors' orders, when there was no nurse documenta-
tion, these months were omitted from calculation of ad-
herence, thereby possibly causing to over-estimation of
adherence.
In addition to measuring adherence, we recorded in-
stances designated as over-adherence, i.e. use of the drug
without doctors’ orders. When an order to stop the drug
was recorded, yet in the following months the medica-
tion was nevertheless purchased, we considered the pa-
tient over-adherent.
Patient purchases of medications in the absence of
clearly identified orders to stop these medications were
excluded from definition of over-adherence. The per-
centage of over-adherence was calculated as the ratio be-
tween the number of months a patient purchased the
medication and the number of months since the order
to stop the drug, extending either until the end of data
collection or until a new order was recorded. For ex-
ample, if an order to stop a medication was given and
followed by 12 months of follow-up, in all of which the
patient continued to purchase the drug and did not in-
form the nurse and nephrologists, the over-adherence
was 100%.Individual patterns of drug practices
In addition to calculating the adherence rate, we found
during data collection that the patterns of medication
purchase and reported intake were inconsistent to the
extent that merely presenting descriptive statistics would
have underscored the patchiness of the phenomenon.
We therefore sought to present the raw data itself to
allow a better appreciation of what we perceived as
therapeutic pandemonium (Figure 1 and Additional file 1:
Figures S2-S12). In these diagrams, drug intake behavior
of individual patients is depicted in each row and each col-
umn represents a calendar month. These comprehensive
plates reflect patient purchase patterns (designated A),
nurse reported intake (designated B), patient adherences
(designated C) and purchase and dose consistencies/dis-
crepancies (designated D) in the form of color medication
plates. Each plate depicts one drug or a family of drugs.
The rows are numbered from 1 to 75 and each represents
a patient in our study. Each patient is consistently repre-
sented by the same number. In all plates, white bars reflect
patient death.
Figure 1 (See legend on next page.)
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Figure 1 Medication purchase, reporting and adherence patterns of ACE inhibitors and ARB’s, in the form of color medication plates.
The plates reflect patient purchase patterns (A), nurse reported intake (B), patient adherence calculations (C) and purchase and dose consistencies
(D). Each row represents a patient and each column represents a month, rows are numbered from 1 to 75 and each represents a patient in our study.
E depicts color coding of the medication plates.
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File allocation and patient survival
Of the 110 eligible HD patients, manual medical records
of 28 patients (25.4%) could not be located in the ar-
chives of the dialysis units and in 7 (6.4%) files, the med-
ical record lacked substantial documents. We therefore
analyzed 75 (68%) patient files with a mean patient fol-
low up time of 23.62 (SD 3.8) months of the planned
25 months.
The mortality rate was lower (17.3%) in the analyzed
group compared to the initial group (29.1%) (Table 2).
Because both drug purchase and intake require either in-
tact cognitive function or assistance, it is of note that
90% of analyzed patients had intact cognition and 61.3%
had access to a caregiver if needed.Clinical indications for drug purchase in HD patients
The frequency of drug use by HD patients is described
in Table 1. There were three major indications for medi-
cations in our HD patients; a. Medications related to min-
eral bone disease comprising 30% of all drugs. b. 36.4% of
drugs purchased were indicated to treat heart failure,
hypertension or arrhythmia (beta or calcium blockers,
ACE inhibitors or ARB, furosemide, doxazosin and anti-
arrhythmics). c. drugs for atherosclerosis (nitrates, aspirin
and statins) comprising 27.2%. Only 4% of oral drugs pur-
chased were indicated for diabetes despite a 10-fold higher
rate of diabetes.Characteristics of drug purchase vs. nurse reports
The electronic CHS purchase database included a total
of 763 medications purchased and 16,410 months of
medication data for the entire study population of 110
patients. The 75 analyzed patients had CHS records
documenting 469/763 (61.5%) medication purchases
during a total of 11,093 months of medication data.
Drugs were purchased only during 4,643 months (41.9%)
of 11,093 months and nurse report of drug intake was
documented in 6,497/11,093 months (58.6%). After cor-
recting for excess medication purchase and accounting
for medication switches within the same class (see
methods), there were 449 drugs used over a period of
10,628 months of medication data. Drugs were pur-
chased during 5,035/10,628 (47.3%) months and nurses
drug reports were documented in 6,510/10,628 months
(61.3%).In 78/6,510 (1%) of these months there were textual
comments in the nurse reports which could not be
quantified (for example “takes when needed”) (Figure 2).
During a follow up period of 25 months, the average
(SD) time span of drug purchase was 11.2 (7.8) months
and the nurse documented patient intake for each drug
was on average (SD) 14.5 (8.0) months (Table 2). Thus,
for most medications, documentation by the nurse
exceeded patient purchases (Figure 3). This difference
was primarily evident for alfacalcidol and calcium carbon-
ate but could also be observed for aspirin, statins and
beta-blockers. For furosemide, calcium channel blockers
and antiarrhythmics, nitrates and doxazosin, the rates of
patient purchase and nurse reporting were similar. The
mean patient-nurse concordant months (months in which
the nurse reported exactly what the patient purchased)
was 5.7 months (95% CI 5.2-6.4), which comprised 50.9%
of the purchase months and 39.3% of the reported intake
months were matched. After excluding calcium carbonate
and alfacalcidol, the mean number of concordant months
was 7.1 (95% CI 6.4-7.8). For example, patient # 2 did not
purchase beta blockers at all throughout the entire
follow-up period, while it was “documented” by the nurse
(Additional file 1: Figures S2-A to S2-D); patient # 54
purchased a higher dose of statins than documented
by the nurse for most of our study period (Additional
file 1: Figure S3-D). Thus, nurses’ reports and actual
patient purchase were often incompatible, sometimes
over long periods.General non-adherence and over-adherence
On average, the overall adherence for all drugs was
56.7% (95% CI 53.6-59.9%) (Figure 4). The adherence to
anti-arrhythmics was high and to calcium carbonate,
alfacalcidol and oral hypoglycemic agents was low. Over-
adherence occurred in 23.6% (95% CI 16.3-30.9%) of the
months following an order to stop medications.
Patterns of individual drug intake, as shown in the
medication plates (Figure 1 and Additional file 1: Figures
S2-S12), indicate that in several cases the medications
had not been purchased for long periods, despite the
nurse reporting medication use. We also noted cases
where a medication was purchased without any nurse
reports. In Figure 1 and Additional file 1: Figures
S2-S12, plates D present regimen comparison between
patient purchase and nurse reporting. In some of the
figures we demonstrate instances where a drug was
Table 2 Baseline characteristics of the study participants
Patients included in analysis
N = 75
Patients randomly chosen for research
N = 110
Age at start of research, Mean/SD 64.55 15.94 65.27 15.35
Died during follow/up, N/% 13 17.3% 32 29.1%
Sex female, N/% 31 41.3% 0.47 42.7%
Transplanted before dialysis, N/% 4 5.3% 5 4.5%
Current smokers, N/total available N/% 10/63 15.9% 12/72 16.7%
Residence during study period, N/total available N*/%
Private residence 64/70 91.4% 72/79 91.1%
assisted living/nursing home 6/70 8.6% 7/79 8.9%
Primary care taker,
N/total available N*/%
Partner 19/57 33.3% 22/79 27.8%
Children 10/57 17.5% 11/79 13.9%
hired care 6/57 10.5% 10/79 12.7%
Other 5/57 8.8% 5/79 6.3%
none/not mentioned 17/57 29.8% 18/79 22.8%
Mental and cognitive disability
N/total available N*/%
No disability 63/70 90.0% 71/78 91.0%
Dementia 2/70 2.9% 2/78 2.6%
Other cognitive/mental disability 5/70 7.1% 5/78 6.4%
Mobility
N/total available N*/%
Mobile 40/61 65.6% 43/67 64.2%
Walking aid 7/61 11.5% 8/67 11.9%
Walker 6/61 9.8% 7/67 10.4%
Wheel chair 8/61 13.1% 9/67 13.4%
*Since the different Dialysis units affiliated with our institute do not document patient information in an identical manner, not all information presented was
availed for all patients. See text and Figure 2 for exclusion criteria.
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the nurse.
As explained in the methods section, plates D do not take
into account cases where the nurse report for that month
was empty. Over-adherence at several levels was noted for
furosemide: we documented only 15 doctors’ orders for
furosemide for 32 patients during 469 patient-months,
much less than would be expected in view of the frequent
changes in medication purchase which were also under-
documented by the nurses (Additional file 1: Figure S7).
Turbulence in physician orders
We documented 632 nephrologists’ orders for changes
in medication regimen (Table 3, Figure 5). Drug turbulence
is a qualitative measure defined as a high rate of change in
physician orders for a given drug. While calcium carbonate
and Alfacalcidol together comprised 33.2% of the drugs inour study, 63.6% of physicians’ orders involved these
two drugs, thereby positioning this class of mineral
bone disease drugs as the major drug class occupying
doctors’ time (Table 3). For comparison, aspirin, pre-
scribed for long periods at a fixed dose, manifested a
very low turbulence rate. However, to more carefully
focus on turbulence associated with non-adherence,
we hypothesized that of all possible physician orders
(i.e. start a new drug or stop, reduce or increase dose,
or switch to another drug within the same group), an
order to increase drug dose would better reflect non-
adherence. Alfacalcidol uniquely required more orders
to increase drug dose than decrease dose (142/281 of
alfacalcidol orders vs. 46/121 for calcium carbonate
and 38/230 for all other medications, Table 3), thereby
reflecting a very high level of non-adherence for this
drug. This finding is further corroborated by the low
Information received from CHS:
110 patients
763 events of drug purchase
16,140 months of drug data
35 patients excluded for 
missing archived data
75 patients included in analysis
469 events of drug purchase
11,093 months of drug data
Corrected for:
1) Excess medication purchase
2) Drug swap within same drug  
family
449 cases of medication purchase
10,528 Months of medication data




78 (1.2%) unquantifiable textual 
notes by nurses
Figure 2 Flow chart showing patients and data inclusion in the study. *CHS-Clalit health services.
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and by its low purchase rate relative to the nurses reports
(Figure 3).
Detailed patterns of drug purchase and adherence
Medication Plates shown in Figure 1 and the Additional
file 1: Figures S2-S12, indicate the drug purchase pat-
terns in the form of color medication plates as described
in methods. Typical patterns of drug purchase, nurse re-
port and adherence for ACE inhibitors and ARBs are
presented in Figure 1 - plate A and plate B show medi-
cation purchase in blue and documentation by the nurse
in green, respectively. Lack of purchase or documentation
is marked in grey. Mismatch between 5A and 5B depicts
pharmacy purchase vs. nurse drug documentation.
The two plates differ substantially with regard to sev-
eral months when patients did not purchase the drug
but the nurses did report usage, and vice versa. While
the descriptive data (Figure 3) indicate a small difference
between patient purchase and nurse reports (10.3 vs.
12.4 months), the plates’ qualitative data in Figure 1 in-
dicate a far more complex discrepancy. For example, in
the case of patient # 3 (first row) although the nurse
documented regular use of the drug, the patient did notpurchase it at all. In the case of patient # 64, on July
2008 the patient stopped using the drug altogether, but
the nurse kept on reporting it is being used.
Figure 1 plate C contrasts and completes the adher-
ence rates presented in Table 2, as it illustrates that the
crude calculated rates do not depict the hectic adher-
ence patterns. Figure 1C shows adherence with doctors’
orders as previously defined; in the month following
nurse documentation, the patient was expected to take
the medication as previously reported, unless instructed
otherwise following a physician’s order. Patient # 3 is
considered non-adherent throughout the whole study
period since the drug had never been purchased al-
though the nurse kept reporting it was taken. Patient # 75
is considered adherent throughout the entire study,
since the drug was purchased and documented by the
nurse throughout the entire study period. The ex-
ample of patient # 5 illustrates drug purchase almost
consecutively from July 2008, but because the nurse
hardly reported drug use, adherence of this patient
could not be determined. Finally, patient # 10 pur-
chased the drug on nine months of the study and the
nurse reported drug use during nine months of the
study, but because these months rarely coincided, this
Figure 3 Differences between nurse reports and actual drug purchase. Error bars indicate 95% confidence interval. A positive value indicates
the nurses documented medication use than actually purchased, A negative value indicate more drugs purchased than reported by nurses.
*Calcium carbonate and alfacalcidol.
Cohen-Glickman et al. BMC Nephrology 2014, 15:170 Page 8 of 12
http://www.biomedcentral.com/1471-2369/15/170patient was considered adherent during only 3 of the
9 months reported by the nurse (33%).
Figure 1 plate D incorporates only cases where the
nurse reported drug intake and demonstrate dosage in-
accuracies. In Figure 1D, patient # 74 purchased a higher
dose of the drug compared to the nurse documentation
(colored tan) for a long consecutive period of time.
There were separate events (marked in brown in Figure 1D)
where the nurse specifically reported no drug use, despite
documented concomitant drug purchase. These patternsFigure 4 Variation of adherence rates among the different drug groudiffer from months when the nurse disregarded the drug
altogether, while the drug was purchased (marked grey in
Figure 1B).
Similarly to the pattern observed for ACE inhibitors
and ARB’s, the online supplementary figures show plates
of beta blockers, statins, aspirin and calcium channel
blockers portraying discrepancies between patient pur-
chase (plates labeled A) and nurse documentation (plates
labeled B). Plates labeled C, which represent adherence to
physician recommendations, indicate only a few patientsps. *Calcium carbonate and alfacalcidol.
Table 3 Doctors' orders in HD units
All medications not including Ca + D Calcium carbonate Alfacalcidol All medications
Start treatment 71 17 36 124
Increase dose 38 46 142 227
Reduce dose 32 36 57 125
Stop the treatment 66 22 46 134
Switch to different drug of the same family 23 23
Total 230 121 281 632
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example for statins, Additional file 1: Figure S3 plate C,
patient # 20 was consistently adherent while patient # 73
was consistently non-adherent). Most patients using statins
were adherent yet demonstrated sporadic non-adherence
periods. Taken together, the above data indicate chaotic
drug intake patterns.
Adherence is higher for symptom-relieving medications
The HD patients studied were more adherent to nitrates,
anti-arrhythmics and doxazosin (Additional file 1: Figures
S3-S5- plates C). These medications also manifested less
frequent discrepancies between nurse reporting and pa-
tient purchase (Additional file 1: Figures S4-S6- plates A,
B, D). This finding could also be demonstrated in Figure 3.
Furosemide (Additional file 1: Figures) appears to have a
unique profile as evident in Additional file 1: Figure
S7 plate A (patient purchase), which is denser than
Additional file 1: Figure S7-B (nurses’ documentation).Figure 5 Doctors’ orders by drug type. The proportion of orders regardThere were many cases where patients purchased the
drug with no nurse documentation, i.e. there is a more
drug purchase than nurse intake documentation. For
example, patient # 60 purchased the drug on seven
months during our study period, but only on one of
these months did the nurse document the patient was
using the medication.
Additional file 1: Figure S7-D (adherence) shows an
overall calculated adherence rate for furosemide of
59.9% (Table 2), yet adherence calculation does not fully
account for compliance with doctors’ orders, since it
does not consider over-use patterns of the drug. This
figure shows frequent purchase of the drug at quantities
higher (tan) or lower (light blue) than reported by the
nurse. Patient #21 purchased more than what was re-
ported since April 2008 until the end of follow-up in all
but one month. The over-adherence rate we present in
this report, in the case of furosemide, does not embody
this medication’s use pattern.ing each drug family, of all orders recorded in our study.
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periods. For example, patient # 33 purchased a lower
quantity of furosemide than reported by the nurse for
the first and last thirds of the study period, and a higher
dose for the second third of the study period. Only on
two months during this time, did the nurse report match
the actual patient purchase (green). Nevertheless, due to
our dichotomous definition of adherence, patient # 33 is
considered highly adherent (91.6%).
Non-adherence to hypoglycemic agents and
antidepressants
We found an unexpected low (44.1%) adherence rate to
oral hypoglycemics (Table 3, Additional file 1: Figure S8).
Several patients were non-adherent for long consecutive
periods while only a few patients were mostly adherent.
Antidepressants also had a low adherence rate (Table 2).
However, due to the low patient number this calculation
is prone to inaccuracies. Interesting patterns of non-
adherence can be derived from the medication plates
(Additional file 1: Figure S9). In several cases the medica-
tion had not been purchased for long periods (patient #
62), while the nurse did report medication use.
Discussion
Our study in outpatient HD units demonstrates flaws in
the process of nurse drug documentation and patient
drug adherence, and a high degree of physician order
turbulence. Our findings support previous reports of
high rates of non-adherence to medication intake among
HD patients, ranging from 15% to 74% [5,7,8,16]. This
report’s novelty stems from the presentation of the hec-
tic drug purchase patterns for a variety of medication
groups. Though patient needs and circumstances often
limit complete alignment with treatment guidelines, the
demonstrated pandemonium is not the result of clinical
reasoning and compromise, but rather a system failure
which allows chaos rather than promoting patient-staff
reconciliation. Thus, the overall consistent efficacy of
pharmacotherapy in the care of our HD patients may be
questionable.
Multiple methods have been studied to measure ad-
herence in the research settings, but no single measure
is considered a gold standard [10,11,17,18]. Although
medication regimen adherence may be described as di-
chotomous, there are several methods of measuring ad-
herence [17]. Assessing adherence in the daily clinical
setting is challenging more than in clinical studies given
less allocated resources, variable objective standards, fre-
quent dosing modifications and medication provision in
long term residence or nursing facilities [10]. In this
context, the innovative methodology we applied provides
a repository of patient and nurse behaviors that is dis-
cordant to previous reports claiming >95% reliability ofmonthly medication reviews and record validation [19].
Manley and colleagues reported 215 drug interviews in
63 patients over five months totaling 2,709 drugs
reviewed in an outpatient HD clinic. They found that there
were less than 5% discrepancies between the electronic
medical record and patient-provided information. How-
ever, the patient-reported information had been first veri-
fied by either the nursing or the medical staff and the low
discrepancy rate probably derived from differences be-
tween these verifications and the medical file registers [19].
There are several reasons why HD patients may be at
particular risk for non-adherence. First, rates of adher-
ence among patients with any chronic disease have been
shown to diminish over time, coupled with the progres-
sive complexity of treating HD patients [5,16]. Addition-
ally, many of the medications prescribed for dialysis
patients have no immediate discernible effects, and past
research has shown that adherence is likely to be highest
for symptom-relieving medications [16].
Our results corroborate this conclusion: nitrates, anti-
arrhythmic agents and doxazosin manifested high adher-
ence rates (Table 2) and fewer discrepancies between
nurse reporting and patient purchase (Additional file 1:
Figures S4-S6). As previously shown in the general
population, anti-arrhythmic agents relieve palpitations
and prevent emergency room visits due to arrhythmia
[20], nitrates alleviate chest pain caused by ischemic
heart disease [21] and doxazosin is effective in reducing
symptoms of prostate hypertrophy as well as reducing
blood pressure [22]. In contrast, adherence to other medi-
cations such as statins or ACE inhibitors may not have an
immediate beneficial effect on patients’ symptoms.
Since the medications in our cohort were similar to
those reported in previous HD cohorts, [23] our findings
of the systematic disengagement between the nurses'
documentation and actual patient purchase is fascinating.
Specifically, the discrepancies included either different
doses of medications or documentations of drugs not pur-
chased at all, or vice versa, drug purchase without nurse
documentation. In some cases these patterns persisted
over long periods. Our results could be explained by inad-
equate patient-nurse communication due to unwillingness
to admit non-adherence, forgetfulness of patients, or lack
of systematic data collection by the dialysis staff.
Under reporting of drug use also may result from un-
reported over-adherence, e.g. to furosemide. Additional
file 1: Figure S7 provides detailed information showing
frequent furosemide overuse while descriptive statistics
result in a mean adherence rate of 59.9%. It is therefore
quite possible that patients are making decisions re-
garding dosing and usage of furosemide without con-
sulting the medical staff. Use of furosemide may also
alleviate symptoms of inter-dialytic weight gain yet it is
baffling that HD patients may obtain prescriptions for
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mary nephrologist.
Taken together, the chaotic patterns of patient behav-
ior and nurse documentation appear to result in phys-
ician ignorance of the true nature of drug intake,
thereby jeopardizing the process of medical decision
making and reasoning. A system failure in data transfer
is apparent and regimen management is misguided. We
believe it is the responsibility of the attending nephrolo-
gists to simplify the medication regimen and reduce
medication burden. At the physician’s discretion, the fol-
lowing strategies may reduce the pill burden in HD
patients:
a. stratification of the medications according to their
relative significance for the individual patient; b. initi-
ation of drugs that have not been shown to improve out-
come in HD patients, such as statins, aspirin, warfarin
and a number of vitamins, may be reconsidered; c. for
medications with a long half-life, adherence can be im-
proved by in-house supervised provision of the drugs
thrice-weekly; d. reducing the dose turbulence of specific
medications, such as phosphate binders, to make drug
dosing easier to remember and adhere to. e. because
multiple care providers prescribe many different drugs
with potential interactions, standard and connected elec-
tronic medical records could be beneficial in monitoring
the dynamics of drug therapy; f. because drug non-
adherence and registration discrepancy are hardly ob-
served for drugs administered parenterally within the
HD unit [19], medications intake could be supervised by
the nursing staff during HD sessions.
The patterns of adherence and lack of accurate docu-
mentation described in this work are likely not unique
to our HD population. Lack of communication, financial
barriers, polypharmacy and inadequate medication recon-
ciliation have been recognized previously as a universal
obstacle to compliance with medical therapy [3,24]. It is
pertinent to establish an honest and non-judgmental rela-
tionship with both patients and dialysis care givers to bet-
ter the credibility of medication use in dialysis patients.
Limitations of the study
One limitation to our study is the small sample of patients
and the failure to locate all medical files for almost a third
(31.8%) of the HD patients who were selected randomly
for the study. Nevertheless, the characteristics of our ana-
lyzed group are similar to previous studies [19,25].
Another limitation may have derived from incomplete
computerized pharmacy dispensing caused by purchas-
ing drugs at a pharmacy not affiliated with CHS. How-
ever, these events are rare because in our healthcare
system HD patients receive most drugs either free of
charge or at a negligible cost at pharmacies affiliated
with CHS.During data analysis, measurement of adherence was
possibly skewed towards overestimation of adherence.
First, we corrected for excess medication purchase.
Second, months preceded by no nurse documentation,
were omitted from calculation in order to avoid non-
adherence designation due to ignorance of doctors’ or-
ders. However, these possible biases do not undermine,
and in fact reinforce our findings regarding the perplex-
ing patterns of drug non-adherence in nurse documenta-
tion and physician orders within chronic HD ambulatory
units.
Conclusions
Non-adherence to medication regimens in HD patients
appears to be diverse as well as extensive. Drug adher-
ence varies among drug groups, among patients, and
over time. The patterns of drug purchase and nurse re-
ports resonate on a frequency that descriptive means
could not tune to. Furthermore, given the above results,
physician decision-making are often misguided and may
be flawed. To address these issues, communications be-
tween HD unit staff and patients, between HD unit staff
and other doctors, and possibly between pharmacies’
datasets and the HD units, should be encouraged. Pa-
tient empowerment and shared responsibilities should
be explored as avenues to restore accuracy in reports
and prescription. Nephrologists may need to acknow-
ledge that HD patient non-adherence is an important
factor in their decision-making process and that reduc-
tion of patients’ pill burden may paradoxically improve
their medical care.
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